Home Healthcare Biotechnology Breast Cancer Diagnostics Market

Breast Cancer Diagnostics Market Size, Share & Trends Analysis Report By Cancer Type (Invasive lobular breast cancer, Ductal carcinoma in situ (DCIS), Triple-negative breast cancer, Inflammatory breast cancer, Others), By Test Type (Clinical Breast Exam, Blood Tests, Imaging Tests, Biopsies, Others), By Stage (Stage I, Stage II, Stage III, Stage IV), By End-User (Hospitals and Clinics, Cancer Diagnostic Centers, Cancer Research Institutes, Ambulatory Surgical Centers, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Breast Cancer Diagnostics Market, By Cancer Type 2022-2034 (USD MILLION/ Units)
    1. Invasive lobular breast cancer
    2. Ductal carcinoma in situ (DCIS)
    3. Triple-negative breast cancer
    4. Inflammatory breast cancer
    5. Others
  2. Breast Cancer Diagnostics Market, By Test Type 2022-2034 (USD MILLION/ Units)
    1. Clinical Breast Exam
    2. Blood Tests
    3. Imaging Tests
      1. Mammogram
      2. MRI
      3. Ultrasound
      4. PET
      5. Others
    4. Biopsies
      1. Excisional biopsy
      2. Incisional biopsy
      3. Core biopsy
      4. Fine-needle aspiration (FNA) biopsy
      5. Others
    5. Others
  3. Breast Cancer Diagnostics Market, By Stage 2022-2034 (USD MILLION/ Units)
    1. Stage I
    2. Stage II
    3. Stage III
    4. Stage IV
  4. Breast Cancer Diagnostics Market, By End-User 2022-2034 (USD MILLION/ Units)
    1. Hospitals and Clinics
    2. Cancer Diagnostic Centers
    3. Cancer Research Institutes
    4. Ambulatory Surgical Centers
    5. Others
  5. Regional Breast Cancer Diagnostics Market
    1. North America
      1. North America Breast Cancer Diagnostics Market By Cancer Type 2022-2034 (USD MILLION/ Units)
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
      2. North America Breast Cancer Diagnostics Market By Test Type 2022-2034 (USD MILLION/ Units)
        1. Clinical Breast Exam
        2. Blood Tests
        3. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        4. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        5. Others
      3. North America Breast Cancer Diagnostics Market By Stage 2022-2034 (USD MILLION/ Units)
        1. Stage I
        2. Stage II
        3. Stage III
        4. Stage IV
      4. North America Breast Cancer Diagnostics Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals and Clinics
        2. Cancer Diagnostic Centers
        3. Cancer Research Institutes
        4. Ambulatory Surgical Centers
        5. Others
      5. U.S.
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
        6. Clinical Breast Exam
        7. Blood Tests
        8. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        9. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        10. Others
        11. Stage I
        12. Stage II
        13. Stage III
        14. Stage IV
        15. Hospitals and Clinics
        16. Cancer Diagnostic Centers
        17. Cancer Research Institutes
        18. Ambulatory Surgical Centers
        19. Others
      6. Canada
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
        6. Clinical Breast Exam
        7. Blood Tests
        8. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        9. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        10. Others
        11. Stage I
        12. Stage II
        13. Stage III
        14. Stage IV
        15. Hospitals and Clinics
        16. Cancer Diagnostic Centers
        17. Cancer Research Institutes
        18. Ambulatory Surgical Centers
        19. Others
    2. Europe
      1. Europe Breast Cancer Diagnostics Market By Cancer Type 2022-2034 (USD MILLION/ Units)
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
      2. Europe Breast Cancer Diagnostics Market By Test Type 2022-2034 (USD MILLION/ Units)
        1. Clinical Breast Exam
        2. Blood Tests
        3. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        4. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        5. Others
      3. Europe Breast Cancer Diagnostics Market By Stage 2022-2034 (USD MILLION/ Units)
        1. Stage I
        2. Stage II
        3. Stage III
        4. Stage IV
      4. Europe Breast Cancer Diagnostics Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals and Clinics
        2. Cancer Diagnostic Centers
        3. Cancer Research Institutes
        4. Ambulatory Surgical Centers
        5. Others
      5. U.K.
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
        6. Clinical Breast Exam
        7. Blood Tests
        8. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        9. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        10. Others
        11. Stage I
        12. Stage II
        13. Stage III
        14. Stage IV
        15. Hospitals and Clinics
        16. Cancer Diagnostic Centers
        17. Cancer Research Institutes
        18. Ambulatory Surgical Centers
        19. Others
      6. Germany
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
        6. Clinical Breast Exam
        7. Blood Tests
        8. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        9. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        10. Others
        11. Stage I
        12. Stage II
        13. Stage III
        14. Stage IV
        15. Hospitals and Clinics
        16. Cancer Diagnostic Centers
        17. Cancer Research Institutes
        18. Ambulatory Surgical Centers
        19. Others
      7. France
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
        6. Clinical Breast Exam
        7. Blood Tests
        8. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        9. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        10. Others
        11. Stage I
        12. Stage II
        13. Stage III
        14. Stage IV
        15. Hospitals and Clinics
        16. Cancer Diagnostic Centers
        17. Cancer Research Institutes
        18. Ambulatory Surgical Centers
        19. Others
      8. Spain
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
        6. Clinical Breast Exam
        7. Blood Tests
        8. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        9. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        10. Others
        11. Stage I
        12. Stage II
        13. Stage III
        14. Stage IV
        15. Hospitals and Clinics
        16. Cancer Diagnostic Centers
        17. Cancer Research Institutes
        18. Ambulatory Surgical Centers
        19. Others
      9. Italy
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
        6. Clinical Breast Exam
        7. Blood Tests
        8. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        9. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        10. Others
        11. Stage I
        12. Stage II
        13. Stage III
        14. Stage IV
        15. Hospitals and Clinics
        16. Cancer Diagnostic Centers
        17. Cancer Research Institutes
        18. Ambulatory Surgical Centers
        19. Others
      10. Russia
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
        6. Clinical Breast Exam
        7. Blood Tests
        8. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        9. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        10. Others
        11. Stage I
        12. Stage II
        13. Stage III
        14. Stage IV
        15. Hospitals and Clinics
        16. Cancer Diagnostic Centers
        17. Cancer Research Institutes
        18. Ambulatory Surgical Centers
        19. Others
      11. Nordic
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
        6. Clinical Breast Exam
        7. Blood Tests
        8. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        9. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        10. Others
        11. Stage I
        12. Stage II
        13. Stage III
        14. Stage IV
        15. Hospitals and Clinics
        16. Cancer Diagnostic Centers
        17. Cancer Research Institutes
        18. Ambulatory Surgical Centers
        19. Others
      12. Benelux
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
        6. Clinical Breast Exam
        7. Blood Tests
        8. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        9. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        10. Others
        11. Stage I
        12. Stage II
        13. Stage III
        14. Stage IV
        15. Hospitals and Clinics
        16. Cancer Diagnostic Centers
        17. Cancer Research Institutes
        18. Ambulatory Surgical Centers
        19. Others
      13. Rest of Europe
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
        6. Clinical Breast Exam
        7. Blood Tests
        8. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        9. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        10. Others
        11. Stage I
        12. Stage II
        13. Stage III
        14. Stage IV
        15. Hospitals and Clinics
        16. Cancer Diagnostic Centers
        17. Cancer Research Institutes
        18. Ambulatory Surgical Centers
        19. Others
    3. APAC
      1. APAC Breast Cancer Diagnostics Market By Cancer Type 2022-2034 (USD MILLION/ Units)
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
      2. APAC Breast Cancer Diagnostics Market By Test Type 2022-2034 (USD MILLION/ Units)
        1. Clinical Breast Exam
        2. Blood Tests
        3. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        4. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        5. Others
      3. APAC Breast Cancer Diagnostics Market By Stage 2022-2034 (USD MILLION/ Units)
        1. Stage I
        2. Stage II
        3. Stage III
        4. Stage IV
      4. APAC Breast Cancer Diagnostics Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals and Clinics
        2. Cancer Diagnostic Centers
        3. Cancer Research Institutes
        4. Ambulatory Surgical Centers
        5. Others
      5. China
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
        6. Clinical Breast Exam
        7. Blood Tests
        8. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        9. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        10. Others
        11. Stage I
        12. Stage II
        13. Stage III
        14. Stage IV
        15. Hospitals and Clinics
        16. Cancer Diagnostic Centers
        17. Cancer Research Institutes
        18. Ambulatory Surgical Centers
        19. Others
      6. Korea
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
        6. Clinical Breast Exam
        7. Blood Tests
        8. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        9. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        10. Others
        11. Stage I
        12. Stage II
        13. Stage III
        14. Stage IV
        15. Hospitals and Clinics
        16. Cancer Diagnostic Centers
        17. Cancer Research Institutes
        18. Ambulatory Surgical Centers
        19. Others
      7. Japan
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
        6. Clinical Breast Exam
        7. Blood Tests
        8. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        9. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        10. Others
        11. Stage I
        12. Stage II
        13. Stage III
        14. Stage IV
        15. Hospitals and Clinics
        16. Cancer Diagnostic Centers
        17. Cancer Research Institutes
        18. Ambulatory Surgical Centers
        19. Others
      8. India
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
        6. Clinical Breast Exam
        7. Blood Tests
        8. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        9. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        10. Others
        11. Stage I
        12. Stage II
        13. Stage III
        14. Stage IV
        15. Hospitals and Clinics
        16. Cancer Diagnostic Centers
        17. Cancer Research Institutes
        18. Ambulatory Surgical Centers
        19. Others
      9. Australia
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
        6. Clinical Breast Exam
        7. Blood Tests
        8. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        9. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        10. Others
        11. Stage I
        12. Stage II
        13. Stage III
        14. Stage IV
        15. Hospitals and Clinics
        16. Cancer Diagnostic Centers
        17. Cancer Research Institutes
        18. Ambulatory Surgical Centers
        19. Others
      10. Singapore
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
        6. Clinical Breast Exam
        7. Blood Tests
        8. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        9. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        10. Others
        11. Stage I
        12. Stage II
        13. Stage III
        14. Stage IV
        15. Hospitals and Clinics
        16. Cancer Diagnostic Centers
        17. Cancer Research Institutes
        18. Ambulatory Surgical Centers
        19. Others
      11. Taiwan
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
        6. Clinical Breast Exam
        7. Blood Tests
        8. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        9. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        10. Others
        11. Stage I
        12. Stage II
        13. Stage III
        14. Stage IV
        15. Hospitals and Clinics
        16. Cancer Diagnostic Centers
        17. Cancer Research Institutes
        18. Ambulatory Surgical Centers
        19. Others
      12. South East Asia
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
        6. Clinical Breast Exam
        7. Blood Tests
        8. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        9. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        10. Others
        11. Stage I
        12. Stage II
        13. Stage III
        14. Stage IV
        15. Hospitals and Clinics
        16. Cancer Diagnostic Centers
        17. Cancer Research Institutes
        18. Ambulatory Surgical Centers
        19. Others
      13. Rest of Asia-Pacific
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
        6. Clinical Breast Exam
        7. Blood Tests
        8. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        9. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        10. Others
        11. Stage I
        12. Stage II
        13. Stage III
        14. Stage IV
        15. Hospitals and Clinics
        16. Cancer Diagnostic Centers
        17. Cancer Research Institutes
        18. Ambulatory Surgical Centers
        19. Others
    4. Middle East and Africa
      1. Middle East and Africa Breast Cancer Diagnostics Market By Cancer Type 2022-2034 (USD MILLION/ Units)
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
      2. Middle East and Africa Breast Cancer Diagnostics Market By Test Type 2022-2034 (USD MILLION/ Units)
        1. Clinical Breast Exam
        2. Blood Tests
        3. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        4. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        5. Others
      3. Middle East and Africa Breast Cancer Diagnostics Market By Stage 2022-2034 (USD MILLION/ Units)
        1. Stage I
        2. Stage II
        3. Stage III
        4. Stage IV
      4. Middle East and Africa Breast Cancer Diagnostics Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals and Clinics
        2. Cancer Diagnostic Centers
        3. Cancer Research Institutes
        4. Ambulatory Surgical Centers
        5. Others
      5. UAE
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
        6. Clinical Breast Exam
        7. Blood Tests
        8. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        9. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        10. Others
        11. Stage I
        12. Stage II
        13. Stage III
        14. Stage IV
        15. Hospitals and Clinics
        16. Cancer Diagnostic Centers
        17. Cancer Research Institutes
        18. Ambulatory Surgical Centers
        19. Others
      6. Turkey
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
        6. Clinical Breast Exam
        7. Blood Tests
        8. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        9. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        10. Others
        11. Stage I
        12. Stage II
        13. Stage III
        14. Stage IV
        15. Hospitals and Clinics
        16. Cancer Diagnostic Centers
        17. Cancer Research Institutes
        18. Ambulatory Surgical Centers
        19. Others
      7. Saudi Arabia
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
        6. Clinical Breast Exam
        7. Blood Tests
        8. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        9. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        10. Others
        11. Stage I
        12. Stage II
        13. Stage III
        14. Stage IV
        15. Hospitals and Clinics
        16. Cancer Diagnostic Centers
        17. Cancer Research Institutes
        18. Ambulatory Surgical Centers
        19. Others
      8. South Africa
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
        6. Clinical Breast Exam
        7. Blood Tests
        8. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        9. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        10. Others
        11. Stage I
        12. Stage II
        13. Stage III
        14. Stage IV
        15. Hospitals and Clinics
        16. Cancer Diagnostic Centers
        17. Cancer Research Institutes
        18. Ambulatory Surgical Centers
        19. Others
      9. Egypt
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
        6. Clinical Breast Exam
        7. Blood Tests
        8. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        9. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        10. Others
        11. Stage I
        12. Stage II
        13. Stage III
        14. Stage IV
        15. Hospitals and Clinics
        16. Cancer Diagnostic Centers
        17. Cancer Research Institutes
        18. Ambulatory Surgical Centers
        19. Others
      10. Nigeria
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
        6. Clinical Breast Exam
        7. Blood Tests
        8. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        9. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        10. Others
        11. Stage I
        12. Stage II
        13. Stage III
        14. Stage IV
        15. Hospitals and Clinics
        16. Cancer Diagnostic Centers
        17. Cancer Research Institutes
        18. Ambulatory Surgical Centers
        19. Others
      11. Rest of MEA
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
        6. Clinical Breast Exam
        7. Blood Tests
        8. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        9. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        10. Others
        11. Stage I
        12. Stage II
        13. Stage III
        14. Stage IV
        15. Hospitals and Clinics
        16. Cancer Diagnostic Centers
        17. Cancer Research Institutes
        18. Ambulatory Surgical Centers
        19. Others
    5. LATAM
      1. LATAM Breast Cancer Diagnostics Market By Cancer Type 2022-2034 (USD MILLION/ Units)
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
      2. LATAM Breast Cancer Diagnostics Market By Test Type 2022-2034 (USD MILLION/ Units)
        1. Clinical Breast Exam
        2. Blood Tests
        3. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        4. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        5. Others
      3. LATAM Breast Cancer Diagnostics Market By Stage 2022-2034 (USD MILLION/ Units)
        1. Stage I
        2. Stage II
        3. Stage III
        4. Stage IV
      4. LATAM Breast Cancer Diagnostics Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals and Clinics
        2. Cancer Diagnostic Centers
        3. Cancer Research Institutes
        4. Ambulatory Surgical Centers
        5. Others
      5. Brazil
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
        6. Clinical Breast Exam
        7. Blood Tests
        8. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        9. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        10. Others
        11. Stage I
        12. Stage II
        13. Stage III
        14. Stage IV
        15. Hospitals and Clinics
        16. Cancer Diagnostic Centers
        17. Cancer Research Institutes
        18. Ambulatory Surgical Centers
        19. Others
      6. Mexico
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
        6. Clinical Breast Exam
        7. Blood Tests
        8. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        9. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        10. Others
        11. Stage I
        12. Stage II
        13. Stage III
        14. Stage IV
        15. Hospitals and Clinics
        16. Cancer Diagnostic Centers
        17. Cancer Research Institutes
        18. Ambulatory Surgical Centers
        19. Others
      7. Argentina
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
        6. Clinical Breast Exam
        7. Blood Tests
        8. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        9. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        10. Others
        11. Stage I
        12. Stage II
        13. Stage III
        14. Stage IV
        15. Hospitals and Clinics
        16. Cancer Diagnostic Centers
        17. Cancer Research Institutes
        18. Ambulatory Surgical Centers
        19. Others
      8. Chile
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
        6. Clinical Breast Exam
        7. Blood Tests
        8. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        9. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        10. Others
        11. Stage I
        12. Stage II
        13. Stage III
        14. Stage IV
        15. Hospitals and Clinics
        16. Cancer Diagnostic Centers
        17. Cancer Research Institutes
        18. Ambulatory Surgical Centers
        19. Others
      9. Colombia
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
        6. Clinical Breast Exam
        7. Blood Tests
        8. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        9. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        10. Others
        11. Stage I
        12. Stage II
        13. Stage III
        14. Stage IV
        15. Hospitals and Clinics
        16. Cancer Diagnostic Centers
        17. Cancer Research Institutes
        18. Ambulatory Surgical Centers
        19. Others
      10. Rest of LATAM
        1. Invasive lobular breast cancer
        2. Ductal carcinoma in situ (DCIS)
        3. Triple-negative breast cancer
        4. Inflammatory breast cancer
        5. Others
        6. Clinical Breast Exam
        7. Blood Tests
        8. Imaging Tests
          1. Mammogram
          2. MRI
          3. Ultrasound
          4. PET
          5. Others
        9. Biopsies
          1. Excisional biopsy
          2. Incisional biopsy
          3. Core biopsy
          4. Fine-needle aspiration (FNA) biopsy
          5. Others
        10. Others
        11. Stage I
        12. Stage II
        13. Stage III
        14. Stage IV
        15. Hospitals and Clinics
        16. Cancer Diagnostic Centers
        17. Cancer Research Institutes
        18. Ambulatory Surgical Centers
        19. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.